Seriously, the more Jason comments on Amarantus, the less credible I believe him to be. Gerald has stated numerous times they will not do a large reverse split just to uplist, and one will only be done from a position of strength. Although the company is close to revenues and several significant milestones, no one could successfully argue that we are currently in a position of strength. That could likely change over the coming months. A large RS at this point would not result in a sustainable share price after the uplist. Jason knows this, which makes such comments questionable at best.

His 2015 LymPro revenue projection is only $1 Million out of a potential $150 Million RUO market. Seriously? Does anyone with a working brain believe that to be anywhere remotely near a realistic projection considering the company's continued discussions with KOLs and tailoring the testing to suit their needs?